Page 31 - Vaccine

Best of BS Opinion: Backsliding without broadband, Covid-19 vaccine & more

Here's a selection of Business Standard opinion pieces for the day

Supply chain threats

Vaccine nationalism shows how the pandemic has stressed trade

A data-driven path to vaccine equity

The relative weightage of economic activities and mortality may be a serious issue, which the policymakers should decide and the model can be rebuilt based on the country's perspective

Wait for Sputnik V Covid-19 vaccine may get over in a few weeks: DRL

"We expect to get the approval in the next few weeks," said Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL)

SII, Bharat Bio seek central fund injection to ramp up vaccine production

SII, Bharat Biotech want to increase production to meet domestic, foreign demand

Gujarat's Covid-19 cases cross 300,000-mark with 2,270 additions

Gujarat's COVID-19 tally crossed the 3-lakh mark and reached 3,00,866 on Sunday with the addition of 2,270 fresh cases, the state health department said.

Increase vaccine supply

Govt must fast-track approval process, fix distribution issues

India delays big exports of AstraZeneca vaccine as Covid-19 cases surge

India is, however, not officially banning Covid-19 vaccine exports. "This is a temporary move until the supply situation stabilises in the country," said a person close to the development

Adar Poonawalla rents London mansion for $69,000 a week, says report

The mansion is one of the largest residences in the neighborhood and measures about 25,000 square feet (2,322 square meters), the equivalent of about 24 average English homes

All above 45 years of age to get Covid-19 vaccine from April 1: Govt

So far, only those above 45 who had certain co-morbidities were allowed to take the vaccine after producing a letter from a registered doctor

One year on

Ravages of last year's lockdown may still affect economy

States on overdrive to reduce vaccine wastage as Covid-19 cases rise

Experts say controlling spoilage with 10-dose vials may give vax drive a shot in the arm

Vardhman Health to invest Rs 100 crore in adult immunisation outreach

Company earned Rs 500 crore as revenue in FY21 and it plans to double it to over Rs 1,000 crore.

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

Approve more vaccines

There are several reasons why we are not yet, as Union Health Minister Harsh Vardhan claimed recently, in the "the endgame" of the pandemic in this country

US export curbs can limit Covid shot production, availability: Poonawalla

The production of coronavirus vaccines and scaling up global availability could be seriously limited due to ban on exports of critical raw materials by the US, according to SII CEO Adar Poonawalla

PM Modi kicks off third phase of vaccination, takes first jab of Covaxin

In the age group of 45-60 years of age around 18,850 got the first dose and more than 128,000 beneficiaries over 60 years of age got the shot on Monday

Covid-19 vaccination: Centres witness enthusiastic response on Day 1

Even as the upgraded Co-WIN was launched, technical glitches continued and many places got off to a late start.

Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

J&J's 1-dose shot cleared, giving US 3rd Covid-19 vaccine

The US is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of two. Health experts are anxiously awaiting a one-and-done option to help speed vaccinations, as they race against a virus that already has killed more than 510,000 people in the US and is mutating in increasingly worrisome ways. The FDA said J&J's vaccine offers strong protection against what matters most: serious illness, hospitalizations and death. One dose was 85% protective against the most severe COVID-19 illness, in a massive study that spanned three continents protection that remained strong even in countries such as South Africa, where the variants of most concern are spreading. The more vaccines that have high efficacy that we can get into play, the better, Dr. Anthony Fauci, the top US infectious disease expert, said ahead of the FDA's ruling. Shipments of a few million doses to be divided ...